Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 14,964 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Recruiting Phase 1 Interventional

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

NCT05746897
View directory record Official record
Conditions
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
NM1F Injection, Pembrolizumab injection
Drug
Lead sponsor
Hefei TG ImmunoPharma Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 29, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol

NCT01697397
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
Recording of Myoelectric Signals
Device
Lead sponsor
G-Tech Corporation
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreas vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 29, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

NCT06269510
View directory record Official record
Conditions
Alcohol-related Liver Disease, Liver Diseases
Interventions
ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 29, 2026, 11:42 AM EDT
Completed No phase listed Observational

Medical and Surgical Treatment of Esophageal Reflux

NCT00061724
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Maywood, Illinois • Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease

NCT01930123
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
intravenous fructose challenge, Blood Draw
Drug · Other
Lead sponsor
Manal F Abdelmalek
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 29, 2026, 11:42 AM EDT
Active, not recruiting No phase listed Observational

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 11:42 AM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

NCT01456052
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Telotristat Etiprate, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Anaheim, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated No phase listed Observational

Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry

NCT06052358
View directory record Official record
Conditions
Atrial Fibrillation, GI Bleeding
Interventions
LAAC with Watchman FLX device
Device
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Phase 1 Interventional

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

NCT01649258
View directory record Official record
Conditions
Breast Cancer, Nausea, Vomiting
Interventions
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Treating Pediatric NAFLD with Nutrition

NCT05499585
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
Interventions
Whole Dairy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

NCT03723915
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pembrolizumab, Wild-type Reovirus
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated No phase listed Observational

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

NCT01759017
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 1 Interventional Results available

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017
View directory record Official record
Conditions
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions
Cabiralizumab, Nivolumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 29, 2026, 11:42 AM EDT
Withdrawn Phase 3 Interventional

Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections

NCT02519140
View directory record Official record
Conditions
Gastric Cancer, Colon Cancer
Interventions
Cook Medical EMR Gel
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

NCT00300950
View directory record Official record
Conditions
Pancreas Cancer
Interventions
GI-4000, Gemcitabine
Biological · Drug
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC Aspirin 325
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NECTAR Study: Nectar (Honey) Effects on Comfort, Thoughts, and Regularity

NCT04187950
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Physiological Stress, Cognition - Other
Interventions
Yogurt with B. lactis and added honey, Yogurt with heat-inactivated B. lactis and added cane sugar
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
22 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Not applicable Interventional

Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers

NCT02057991
View directory record Official record
Conditions
Anxiety Disorder, Colon Cancer, Depression, Fatigue, Rectal Cancer
Interventions
educational intervention, CAM exercise therapy, caregiver-related intervention or procedure, questionnaire administration, laboratory biomarker analysis
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

NCT01396213
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide Acetate, placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 29, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

NCT00560560
View directory record Official record
Conditions
Colorectal Neoplasm
Interventions
CP-751, 871
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 29, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Results available

Gemcabene for the Treatment of Pediatric NAFLD

NCT03436420
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Gemcabene
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 29, 2026, 11:42 AM EDT